Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 1
Submit an article Journal homepage
848
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Letter to the editor regarding “Budget impact analysis of pneumococcal conjugate vaccines in Colombia”

Juan M. Reyesa Health Economics and Ouctomes Research, Pfizer SAS, Bogotá, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0806-7173View further author information
ORCID Icon,
Jorge LaRottab Vaccine Medical, Pfizer SAS, Bogota, ColombiaORCID Iconhttps://orcid.org/0000-0003-3262-200XView further author information
ORCID Icon,
Natalia Castanoa Health Economics and Ouctomes Research, Pfizer SAS, Bogotá, ColombiaORCID Iconhttps://orcid.org/0000-0001-7383-6800View further author information
ORCID Icon,
Mark A. Fletcherc Vaccine Medical and Scientific affairs, Pfizer Inc, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-2660-8730View further author information
ORCID Icon,
Matthew Wassermand Outcome Research, Pfizer Inc, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-3300-2742View further author information
ORCID Icon,
Johnna Perdrizetd Outcome Research, Pfizer Inc, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-4260-7607View further author information
ORCID Icon &
Rodrigo Sini de Almeidae Vaccine Medical and Scientific affairs, Pfizer Inc, Sao Paulo, BrazilView further author information
 show all
Pages 1-3 | Received 03 May 2021, Accepted 23 Sep 2021, Published online: 04 Oct 2021
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Declaration of interests

Each of the authors of this letter to the editor are employees of Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editor disclosures

The editor who approved this letter for publication has no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This work was sponsored by Pfizer Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.